PIACENTINI, Federico
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 22.953
EU - Europa 14.506
AS - Asia 12.253
SA - Sud America 1.754
AF - Africa 353
OC - Oceania 75
Continente sconosciuto - Info sul continente non disponibili 23
Totale 51.917
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 22.530
IT - Italia 4.502
SG - Singapore 3.818
CN - Cina 3.091
GB - Regno Unito 2.536
IE - Irlanda 2.196
HK - Hong Kong 1.476
VN - Vietnam 1.383
BR - Brasile 1.277
DE - Germania 1.174
SE - Svezia 1.022
FR - Francia 561
FI - Finlandia 540
RU - Federazione Russa 481
UA - Ucraina 400
IN - India 391
KR - Corea 344
TR - Turchia 288
ID - Indonesia 287
CA - Canada 214
NL - Olanda 199
BG - Bulgaria 179
BD - Bangladesh 161
AR - Argentina 156
TW - Taiwan 144
JP - Giappone 142
MX - Messico 129
IQ - Iraq 120
ES - Italia 103
PL - Polonia 103
ZA - Sudafrica 81
LT - Lituania 77
PK - Pakistan 75
CO - Colombia 73
AU - Australia 72
CL - Cile 68
BE - Belgio 65
MY - Malesia 61
AE - Emirati Arabi Uniti 60
EC - Ecuador 59
EG - Egitto 58
AT - Austria 52
VE - Venezuela 52
CZ - Repubblica Ceca 45
SA - Arabia Saudita 43
PH - Filippine 42
IR - Iran 41
JO - Giordania 38
MA - Marocco 38
KE - Kenya 34
TH - Thailandia 30
PY - Paraguay 29
NP - Nepal 28
RO - Romania 28
CH - Svizzera 27
UZ - Uzbekistan 27
AL - Albania 23
IL - Israele 22
MD - Moldavia 22
TN - Tunisia 22
AZ - Azerbaigian 20
DZ - Algeria 20
GR - Grecia 20
HU - Ungheria 19
DO - Repubblica Dominicana 18
ET - Etiopia 17
EU - Europa 17
NG - Nigeria 17
PT - Portogallo 16
PE - Perù 15
DK - Danimarca 14
SI - Slovenia 14
BO - Bolivia 13
LB - Libano 13
MK - Macedonia 13
JM - Giamaica 12
SY - Repubblica araba siriana 12
LV - Lettonia 11
BH - Bahrain 10
CR - Costa Rica 10
KZ - Kazakistan 10
OM - Oman 10
RS - Serbia 10
UY - Uruguay 10
AO - Angola 9
BY - Bielorussia 9
CI - Costa d'Avorio 9
PA - Panama 9
CY - Cipro 8
HN - Honduras 8
MT - Malta 8
QA - Qatar 8
SK - Slovacchia (Repubblica Slovacca) 8
HR - Croazia 7
KG - Kirghizistan 7
SN - Senegal 7
KW - Kuwait 6
LK - Sri Lanka 6
PS - Palestinian Territory 6
BA - Bosnia-Erzegovina 5
Totale 51.800
Salva come PNG Salva come JPEG
Città #
Singapore 2.566
Santa Clara 2.381
Ashburn 2.378
Dublin 2.188
Fairfield 1.752
Chandler 1.433
Hong Kong 1.422
Southend 1.325
San Jose 1.072
Woodbridge 1.012
Houston 790
Beijing 746
Dearborn 735
Seattle 717
Nyköping 668
Ann Arbor 666
Hefei 629
Wilmington 624
Jacksonville 608
Cambridge 535
London 520
Council Bluffs 488
Dallas 486
Ho Chi Minh City 436
New York 424
Milan 403
Helsinki 401
Los Angeles 372
The Dalles 363
Modena 332
Hanoi 309
Seoul 300
Rome 280
Jakarta 226
Chicago 225
Munich 207
Lauterbourg 196
Shanghai 195
San Diego 182
Bologna 177
Princeton 174
Sofia 169
Moscow 157
Eugene 141
Izmir 132
São Paulo 123
Frankfurt am Main 116
Dong Ket 112
Orem 107
Fremont 105
Redwood City 104
Buffalo 95
Tokyo 88
Naples 81
Columbus 78
Bremen 77
Salt Lake City 76
Warsaw 74
Florence 71
Guangzhou 68
Falls Church 67
Phoenix 66
Brooklyn 61
Boardman 59
Reggio Emilia 58
Turin 58
Redondo Beach 56
Taichung 56
Da Nang 55
Chennai 53
Baghdad 49
Bari 49
Brussels 49
Genoa 49
Haiphong 49
Mumbai 49
Parma 49
Tampa 48
Atlanta 46
Amsterdam 45
Nuremberg 44
Turku 44
Norwalk 43
Palermo 42
Toronto 41
Rio de Janeiro 40
Elk Grove Village 39
Montreal 39
Johannesburg 38
Des Moines 37
Ottawa 37
San Francisco 37
Nanjing 36
Paris 36
Denver 35
San Giuliano Milanese 35
Stockholm 35
Mexico City 34
Santiago 33
Enfield 32
Totale 34.745
Salva come PNG Salva come JPEG
Nome #
VALORE PROGNOSTICO E PREDITTIVO DI p53 NEL CARCINOMA MAMMARIO TRATTATO CON CHEMIOTERAPIA NEOADIUVANTE 1.136
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. 594
Oxford Manuale di Medicina Clinica 532
Abemaciclib: eventi avversi e riduzione di dose. 518
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVO 480
Endocrine sensitive metastatic breast cancer and bone only disease: are the new treatments always better? 448
RISULTATI DELLA RADIOTERAPIA PANENCEFALICA (WBRT) NELLE METASTASI CEREBRALI DA CARCINOMA DELLA MAMMELLA: STUDIO RETROSPETTIVO SUL RUOLO PROGNOSTICO DEI FATTORI BIOLOGICI 442
Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer 426
GD2 expression in breast cancer. 419
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 418
SVILUPPO DI IPOGAMMAGLOBULINEMIA IN PAZIENTI TRATTATI CON IMATINIB PER LEUCEMIA MIELOIDE CRONICA O TUMORI STROMALI GASTROINTESTINALI 412
Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor 408
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. 405
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer 402
Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients 396
Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going 390
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): A randomised, open-label, multicentre, phase 2 trial 387
ERBB2 mutations in hormone receptor positive primary breast cancers samples and in their matched endocrine-resistant recurrences. 381
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. 378
SOLUBLE TRAIL-ARMED HUMAN AD-MSC AS NOVEL CELL THERAPY APPROACH FOR PANCREATIC DUCTAL ADENOCARCINOMA 374
Interstitial Lung Disease in Abemaciclib-treated Patients during SARS-CoV-2 Pandemic: A Case Series. 374
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. 373
Clinical and molecular analysis of long-term HER2 positive metastatic breast cancer survivors. 372
MODULAZIONE DELL’ESPRESSIONE DI BIOMARCATORI E PROGNOSI IN PAZIENTI AFFETTE DA CARCINOMA MAMMARIO OPERABILE SOTTOPOSTE A CHEMIOTERAPIA PREOPERATORIA 368
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. 367
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 367
Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer 365
Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB) 361
Genomic alterations at the basis of treatment resistance in metastatic breast cancer: Clinical applications 360
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER 356
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: A real-world experience 353
Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial 353
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus 352
Clinical Prognosticators in Patients Treated with CDK 4/6 Inhibitors for Hormone Receptors Positive Advanced Breast Cancer 345
Impact of body composition parameters on tumor response to neoadjuvant chemotherapy in operable breast cancer patients. 344
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. 343
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial . 336
Molecular Profile, as detected with Mass-Array Spectrometry (Sequenom platform), in primary and metastatic breast carcinoma treated with Exemestane + Everolimus 333
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer 333
Tumor Stroma Manipulation By MSC 329
3* Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer 328
Achievements and unmet needs in the management of advanced ovarian cancer 325
Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis 325
Axillary Ectopic Carcinoma of the Breast. Report of Two Cases with Different Clinical Presentation and Review of the Literature. 325
Primary and secondary prevention to effectively reduce the risk of bisphosphonate-related osteonecrosis of the jaw in patients with bone metastases . 323
Predictive role of haemoglobin on disease response to neoadjuvant chemotherapy in breast cancer. 321
Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer. 320
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 318
Post-surgical pyoderma gangrenosum of the breast: needs for early diagnosis and right therapy. 317
CHER LOB Trial: Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer--Safety report as per Independent Data Monitoring Committee (IDMC) and preliminary activity data 314
A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 310
Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy 310
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status 309
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis 306
Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review. 305
Impact of time to surgery after neoadjuvant chemotherapy in patients with operable breast cancer. 304
Immune characterization of breast cancer metastases: prognostic implications. 302
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis 300
Molecular profile in primary and metastatic breast cancer treated with Exemestane and Everolimus. 299
Preoperative chemotherapy plus lapatinib or trastuzumab or both in Her2 positive operable breast cancer. EGF109085-LAP106988/CHERLOB Trial. 299
Primary pulmonary cancer colliding with metastatic breast carcinoma: hitherto unreported cases of cancer-to-cancer metastasis focusing on clinical implications 298
Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial). 298
Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid. 294
Safety and efficacy of T-DM1 in HER2 positive metastatic breast cancer patients: a real word experience. 293
Double-blind, placebo-controlled, multicentric randomized phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal HER2-negative, hormone receptor-positive operable breast cancer 293
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients 292
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 292
Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials. 291
Ki67 as a Predictor of Response and Long Term Survival in Hormone Receptor Positive/HER2 Negative Breast Cancer Patients Treated with Preoperative Chemotherapy 288
Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat? 285
Prognostic significance of germline BRCA mutations in patients with HER2-positive breast cancer. Epidemiological analysis in primary BRCA screens 282
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer 281
Breast Location for De Novo Extramedullary Myeloid Sarcoma 281
Clinical-Pathological Characteristics of HER2+ Breast Cancers patients among BRCA1/2+ carriers tested in Modena Cancer Center. 281
Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer 276
Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era 271
Preoperative Carboplatin–Paclitaxel–Bevacizumab in Triple-Negative Breast Cancer: Final Results of the Phase II Ca.Pa.Be Study 269
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in patients with HER2-positive operable breast cancer 268
9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio 266
Magnetic resonance imaging and ultrasonography in predicting pathologic extent after preoperative chemotherapy in stage II-III breast cancer 264
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 264
Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. 264
Thromboembolism (TE) and adjuvant endocrine therapy (AET) in hormone receptor positive (HR+) early breast cancer (EBC): Did the evolution of treatment change the incidence of the adverse event? A metanalysis 264
PREVALENCE OF NODE NEGATIVE AND SMALL SIZE TUMORS IN A NATIONAL, RANDOMISED, PHASE III ADJUVANT TRIAL IN HER2 + EARLY BREAST CANCER (SHORT-HER STUDY) 261
Predictors of HER2 gene amplification in immunohistochemistry score 2+ Early Breast Cancer according to 2018 ASCO/CAP guidelines: a single institution analysis. 261
Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer 259
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status. 258
PROLIFERATION AND APOPTOSIS BEFORE AND AFTER PRIMARY SYSTEMIC THERAPY FOR OPERABLE BREAST CANCER 256
Preoperative carboplatin-paclitaxel-bevacizumab in triple negative breast cancer: Final results of the phase II CA.Pa.Be study 255
Impact of anaemia on tumor response to neoadjuvant chemotherapy in breast cancer patients . 255
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials (Breast Cancer Research and Treatment, (2017), 163, 2, (295-302), 10.1007/s10549-017-4191-y) 254
Prognostic Factors for Breast Cancer: an Immunomorphological Update 252
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 252
35. PREDICTORS OF HER2 FISH POSITIVITY IN PRIMARY BREAST CANCER DIAGNOSIS SCORED 2+ WITH IHC: RESULTS OF A SINGLE INSTITUTION ANALYSIS 251
PROGNOSIS AND RESPONSE TO NEOADJUVANT CHEMOTHERAPY ACCORDING TO HER2 EXPRESSION IN EARLY BREAST CANCER: a retrospective single institution analysis 247
Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges 245
Prognostic impact of estrogen receptor (ER) level changes during progression for patients with both ER-positive (ER+) primary breast cancer and paired recurrence 245
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 245
STRATEGIES TO PREDICT TREATMENT RESPONSE AND SELECT THERAPIES IN METASTATIC BREAST CANCER PATIENTS USING A NEXT GENERATION SEQUENCING MULTI-GENE PANEL 244
STRATEGIES TO PREDICT TREATMENT RESPONSE AND SELECT THERAPIES IN METASTATIC BREAST CANCER PATIENTS USING A NEXT GENERATION SEQUENCING (NGS) MULTI-GENE PANEL 243
Totale 33.428
Salva come PNG Salva come JPEG
Categoria #
all - tutte 177.018
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 177.018
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021654 0 0 0 0 0 0 0 0 0 0 345 309
2021/20223.347 133 383 286 129 124 264 152 199 366 301 594 416
2022/20236.484 494 585 344 417 410 514 111 388 2.573 114 324 210
2023/20243.682 173 201 238 287 492 312 332 568 150 204 290 435
2024/20259.735 352 206 264 720 1.865 1.489 613 692 960 579 766 1.229
2025/202616.771 1.195 595 1.599 1.818 2.716 1.246 2.448 1.036 1.798 1.936 384 0
Totale 52.307